Application of Comprehensive Non-invasive Assessment To Phenotype Tricuspid Regurgitation
NCT07042360 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 450
Last updated 2025-06-29
Summary
Tricuspid regurgitation (TR) is an increasingly recognized valvular heart disease associated with high morbidity and mortality. With the availability of various novel transcatheter tricuspid interventions, it is no longer considered a "forgotten valve." Heart failure with preserved ejection fraction (HFpEF) is a prevalent condition also characterized by high morbidity and mortality. The prevalence of moderate to severe TR in the general population is 3% to 6%; however, in patients with heart failure (with reduced or preserved ejection fraction \[EF\]), the prevalence is 10% to 29%, rising to up to 39% in patients with HFpEF and atrial fibrillation (AF). The EuroTR registry, an international registry including patients who underwent percutaneous treatment for severe TR, reported that 72% of patients had a left ventricular ejection fraction (LVEF) ≥50%. In a subgroup of patients with right heart catheterization data, 68% had a pulmonary capillary wedge pressure (PCWP) ≥15 mm Hg, indicating that many of these patients may have HFpEF. Patients with significant TR have also been shown to experience irreversible liver derangement and cirrhosis. Non-invasive evaluation of liver stiffness (LS), measured by transient elastography, has recently received increased attention in patients with heart failure and has been shown to closely correlate with right-sided filling pressures. LS has been used to predict adverse outcomes in patients undergoing transcatheter aortic valve (TA) surgery with concomitant left-sided valve surgery.
On the other hand, the Remote Dielectric Sensing System (ReDS; Sensible Medical Innovations, Israel) is a device that measures lung fluid non-invasively and provides an objective and reproducible index of volume status. It is an FDAapproved device for heart failure patients. ReDS measurements are presented as the percentage of fluid relative to lung volume, with normal values ranging between 20% to 35%. Studies have demonstrated excellent correlations between the ReDS index and computed tomography (CT)-measured lung water and invasively determined hemodynamics. Additionally, it has been shown to predict heart failure rehospitalization in patients with acute heart failure.
Given the emergence of novel transcatheter tricuspid interventions and the established link between TR, HFpEF, and markers such as liver stiffness and lung fluid index (measured by ReDS), this study will examine the intricate interplay between these conditions and their shared pathophysiology. By analyzing left and right heart function, risk factors, and treatment outcomes, the research aims to phenotype TR using non-invasive assessment tools to predict clinical outcomes and improve treatment strategies for patients with different types of TR. Our findings will contribute to developing more effective and personalized treatment plans for patients with TR.
Conditions
- Tricuspid Regurgitation
Interventions
- DIAGNOSTIC_TEST
-
ReDs Pro
The basic principle invovles emitting low-power electromagnetic sgnals into the lungs and measuring the dielectric properties of lung tissue The varing dielectric constants of these components result in differences in the impedance values for electromagnetic waves. Therefore, using the impedance method allows the estimation of the dielectric properties of lung tissue, which can be further converted into lung fluid content data through calculations.
- DIAGNOSTIC_TEST
-
Fibroscan
Using external ultrasound scanner to check fo rliver stiffness using acoustic energy
Sponsors & Collaborators
-
Prince of Wales Hospital, Shatin, Hong Kong
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-04-01
- Primary Completion
- 2025-12-31
- Completion
- 2029-03-31
Countries
- Hong Kong
Study Locations
More Related Trials
-
Feasibility Study of the DragonFly-T System for Severe Tricuspid Regurgitation
NCT05671640 ·Status: UNKNOWN ·Phase: NA
-
The Long-term Course of Moderate Tricuspid Regurgitation
NCT06169345 ·Status: COMPLETED
-
Minimally Invasive Tricuspid Surgery vs Medical Treatment for Severe TR
NCT04339192 ·Status: UNKNOWN ·Phase: NA
-
Behaviour of Tricuspid Valve Regurgitation in Volume and/or Pressure Loaded Right Heart
NCT01444222 ·Status: COMPLETED
-
Evaluation of Tricuspid Valve Percutaneous Repair System in the Treatment of Severe Secondary Tricuspid Disorders
NCT04646811 ·Status: COMPLETED ·Phase: NA
-
A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Efficacy and Safety of the Transcatheter Tricuspid Valvuloplasty System in Patients With Severe or Above Tricuspid Regurgitation
NCT05770648 ·Status: UNKNOWN ·Phase: NA
-
The Right Ventricular Pulmonary Circulation Continuum in Mitral Valve Disease Study
NCT03155373 ·Status: COMPLETED
-
Risk Stratification in Severe Treatment-naive, Tricuspid Regurgitation
NCT04173091 ·Status: UNKNOWN
-
Outcome of Patients With Severe Functional TR According to Medical, Transcatheter or Surgical Treatment
NCT05825898 ·Status: ENROLLING_BY_INVITATION
-
Prospective Registry of Patients With Isolated Severe Tricuspid Regurgitation
NCT01502462 ·Status: COMPLETED
-
Application of FAPI Visualization in the Assessment of Right Ventricular Dysfunction Due to Volume Overload
NCT06663566 ·Status: ENROLLING_BY_INVITATION
-
Characterization and Outcomes of Patients Screened for Transcatheter Tricuspid Valve Replacement
NCT06862765 ·Status: COMPLETED
-
TARGET Study: Safety and Performance of the Cardiovalve TR Replacement System
NCT05486832 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Concomitant Tricuspid Repair in Patients With Left Heart Surgery
NCT05595187 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Surgical Treatment of Tricuspid Valve Regurgitation in Patients With Cardiac Implantable Electronic Devices: Long Term Results
NCT05774821 ·Status: COMPLETED
-
Evaluation of the Impact of Tricuspid Regurgitation on Patients Lives. Exploration of Experience and Impact on a Daily Basis.
NCT05532956 ·Status: UNKNOWN
-
Feasibility Study of Treating Tricuspid Regurgitation With K-ClipTM Transcatheter Annuloplasty System
NCT05434507 ·Status: RECRUITING ·Phase: NA
-
Transcatheter Tricuspid Valve Replacement Using the Lux-Valve Plus System
NCT06714500 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Patients With Severe TrIcuspid Regurgitation After triCvALve System Implantation
NCT05820516 ·Status: RECRUITING
-
Tricuspid RegUrgitaTion Hamburg Cohort
NCT04755842 ·Status: RECRUITING
-
The Asia-Pacific Mitral & Tricuspid Valve-in-Valve/Valve-in-Ring Registry
NCT07296016 ·Status: NOT_YET_RECRUITING
-
The Comparison of Tricuspid Replacement and Repair in Patients With Combined Heart Valve Disease
NCT01246141 ·Status: COMPLETED
-
The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement
NCT02644616 ·Status: COMPLETED ·Phase: PHASE4
-
Echo-Guided Tricuspid Valve Surgery Vs. Conservative Approach
NCT03278418 ·Status: UNKNOWN ·Phase: NA
-
Safety and Effectiveness Study of DragonFly-T System for Severe Tricuspid Regurgitation
NCT05556460 ·Status: RECRUITING ·Phase: NA